Erasca (ERAS)

• Market cap: $3.22B
• 1 day: 9.26%
• 5 days: 14.13%
• 1 month: 203.47%
• 3 months: 339.33%
• 6 months: 517.65%
• Year to date: 192.48%
• 1 year: 444.04%
• 5 years: -39.76%
• 10 years: -39.76%
• Sector: Healthcare
• Industry: Biotechnology

About: Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Employees: 129